BioVex Inc, a private biotechnology company developing new generation
biologics for the treatment of cancer and prevention of infectious
disease, announced today that the first subject had been dosed in the
Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2.
The Phase 1 study is an open label ascending dose trial, assessing
safety and immune response in healthy volunteers. The study is taking
place in the UK at the Chelsea and Westminster Hospital in London and
will involve up to 42 already identified subjects. The principle
investigator is Dr. Simon Barton.
“The trial is already fully
enrolled but to follow updates people can check the ‘What’s New’ page on
our website: www.herpes.org.uk,
and for more general information on herpes simplex, check the other
pages or phone our helpline on +44 845 123 2305.”
“Developing an effective vaccine against genital herpes has historically
proved challenging. ImmunoVEX is a rationally designed live attenuated
vaccine specifically constructed to address the limitations of previous
vaccines. We believe our vaccine is built on sound science, providing a
solid basis upon which to anticipate success in the clinic. We look
forward to evaluating the Phase 1 data in late 2010 and based on
positive outcomes, moving ImmunoVEX into later stage efficacy trials
soon thereafter,” said Dr. Robert Coffin, Founder & CTO for BioVex.